Milan, Italy (September 10, 2025)
MgShell, an innovative Italian medtech company developing next-generation magnesium-based drug-delivery solutions, is proud to announce an expansion of its Advisory Board with the appointment of five new internationally recognized experts.
This strategic development marks an important milestone in MgShell’s mission to advance breakthrough solutions at the intersection of material science, drug-delivery, and clinical translation, and to strengthen its scientific and industrial leadership by involving renowned specialists across multiple domains.
The company has officially welcomed the following members to its Advisory Board: Andrea Giani, Emilio Merlo Pich, Diego Mantovani, Andrea Zambon, and Simon Pegg.
About the new Advisory Board members:
Andrea Giani, MD, is a recognized key opinion and industry leader, former Global Head of Medicine for Retinal Health at Boehringer Ingelheim. He is a retinal specialist with great expertise in the retinal industry field. His extensive knowledge and contributions position him at the forefront of advancements in retinal medicine, driving significant progress in treatment options and patient outcomes.
“I am convinced that MgShell has the potential to revolutionize retinal health by addressing a significant unmet medical need through its innovative approach. The technology can reduce the burden on patients, improving treatment adherence and leading to better real-world outcomes in terms of efficacy and safety.”
Emilio Merlo Pich, MD, PhD, is a neurologist and pharmacologist with decades of experience in global pharma R&D. He has held senior leadership positions at Roche, GSK, Takeda, and Alfasigma and he has contributed to translational and pre-clinical development strategies across CNS and other therapeutic areas.
“Innovative materials like those developed by MgShell can reshape how we think about drug-device convergence. I look forward to supporting the team in building the pre-clinical evidence needed to unlock their full therapeutic potential and help the company close the gap with the clinic.”
Diego Mantovani, PhD, is a Professor at Laval University, in Québec, Canada, and a leading international authority in the field of bioresorbable metallic biomaterials and bioengineering. He advises regulatory bodies and industry players on the clinical translation of implantable bioresorbable medical technologies, including those based on magnesium biomaterials.
“MgShell’s innovation in magnesium-based devices represents a meaningful evolution in bioresorbable technology. I’m excited to contribute to their path toward safe and effective clinical adoption, deeply exploring the potential of magnesium-based technology for improving Global Patient’s Health.”
Andrea Zambon is an international expert in the global development of the primary drug packaging sector. He has been the Senior Director of Corporate Business Development at global drug packaging companies, where he played a key role in the advancement of parenteral primary packaging platforms in various regions and now holds the role of Chief Strategy Officer in an important company in cosmetic primary packaging.
“I had the privilege of meeting the MgShell team a few years ago and seeing their technology, with revolutionary potential in ophthalmology and promising applications in other pharmaceutical areas. I was impressed by their depth of knowledge and preparation at all stages, from R&D to advanced stages of the project.”
Simon Pegg, a CMC consultant, is a multi-skilled scientific leader with over 29-year experience in the successful delivery of projects as a CMC project lead, manager and director in small molecules, biologics and cell/gene therapies. He has a recognised cross-discipline expertise with experience of leading numerous initiatives and projects, stage gates, in partnership with CMOs and CROs.
“The future of intravitreal therapies lies in combining pharmacological precision with innovative delivery platforms. MgShell is addressing this need with a compelling approach. I’m pleased to support the team in advancing its scientific validation and clinical translation.”
Commenting on these strategic appointments, Marco Ferroni, CEO of MgShell, said:
“We are honored to welcome such a distinguished group of experts to our Advisory Board. Their combined experience across science, industry, and clinical development will be instrumental in shaping MgShell’s growth and ensuring our innovation reaches patients in a safe, meaningful, and scalable way.”
About MgShell:
MgShell, headquartered in Milan, Italy, is a preclinical-stage drug delivery company focused on developing a magnesium-based drug delivery platform capable of reshaping patient care, enhancing treatment adherence for patients suffering from retinal diseases, and lowering healthcare expenses.
